Latest Breaking News On - Chronic medical - Page 2 : comparemela.com

AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data

Building on expertise in RSV prevention, acquisition will accelerate ambition to deliver portfolio of protective interventions to address high unmet needs in infectious diseases .

New yorkUnited statesUnited kingdomAdrian kempAdam simpsonIskra reicIcosavax incIsochrone merger sub incHoldings incCompany secretaryDrug administrationInvestor relations teamUniversity of washingtonExchange commissionInstitute for protein designImmune therapies

AstraZeneca : to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II data - Form 6-K -December 12, 2023 at 06:30 am EST

a4665w FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or.

United statesNew yorkUniversity of washingtonUnited kingdomAdam simpsonIskra reicAdrian kempInvestor relations teamRegulatory news serviceCompany secretaryCommission file numberIcosavax incHoldings incDrug administrationIsochrone merger sub incSecurities exchange

AstraZeneca to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II data

AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. The proposed acquisition will build on .

New yorkUnited statesUnited kingdomAdam simpsonIskra reicDrug administrationInstitute for protein designUniversity of washingtonHoldings incIsochrone merger sub incIcosavax incExchange commissionInvestor relations teamImmune therapiesExecutive vice presidentChief executive

New Data for AREXVY, GSK s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease

New Data for AREXVY, GSK s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited kingdom generalTony woodUs centers for diseaseCenters for diseaseDrug administrationJapan ministry of healthForum infect disAdvisory committee on immunization practicesAntigenics incProduct serviceNational foundation for infectious diseasesAgenus incEuropean commissionShow potentialHelp protect adults aged

GSK : Japan s Ministry of Health, Labour and Welfare approves GSK s Arexvy, the country s first respiratory syncytial virus (RSV) vaccine for older adults -September 25, 2023 at 02:07 am EDT

Arexvy s approval will help protect adults 60 years of age and older in Japan from RSV disease for the first time, including those living with underlying medical conditions who are.

United kingdomTony woodEuropean commissionJapan ministry of healthStatistics bureau home page population estimates monthlyCenters for diseaseAntigenics incSaponiqx incAgenus incDrug administrationChief scientific officerAdult respiratory syncytial virusNew england journalProduct informationAnnual reportDisease control